NCT02663102 - Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea. | Biotech Hunter

Enrollment

1,388

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

February 5, 2021

Study Completion Date

February 5, 2021

Conditions

Influenza, Human

Interventions

OTHER

Data collection

Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.

Trial Locations (21)

7499

GSK Investigational Site, Seoul

11456

GSK Investigational Site, Yangju-si, Gyeonggi-do

16388

GSK Investigational Site, Suwon-si, Gyeonggi-do

22214

GSK Investigational Site, Incheon

25768

GSK Investigational Site, Donghae

39230

GSK Investigational Site, Gyeongsangbuk-do

42274

GSK Investigational Site, Daegu

42601

GSK Investigational Site, Daegu

47545

GSK Investigational Site, Busan

138201

GSK Investigational Site, Seoul

683380

GSK Investigational Site, Ulsan

700 712

GSK Investigational Site, Daegu

484 5

GSK Investigational Site, Gwangmyeong

03181

GSK Investigational Site, Seoul

03722

GSK Investigational Site, Seoul

03966

GSK Investigational Site, Seoul

04143

GSK Investigational Site, Seoul

04168

GSK Investigational Site, Seoul

06568

GSK Investigational Site, Seoul

08737

GSK Investigational Site, Seoul

135-720

GSK Investigational Site, Seoul